• Moleculin Biotech flagged continued encouraging blinded remission trends in pivotal MIRACLE trial of Annamycin plus cytarabine in relapsed or refractory acute myeloid leukemia, supporting its push toward a potential late-stage inflection point.
• Early blinded results have already been presented, showing patients are responding at a level management views as meaningful in a hard-to-treat population.
• First interim unblinding is expected in June 2026 following enrollment of 45 subjects, setting up a near-term readout that could reshape development strategy and investor expectations.
• Trial enrollment is advancing toward 90 subjects in Q3 2026, with another unblinding planned, followed by start of Part B in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-017226), on May 15, 2026, and is solely responsible for the information contained therein.